CMKLR1 and atherosclerosis: Specifically, the authors identified 18-HEPE as a plasma biosynthetic pathway marker of EPA supplementation, and characterized the receptor for the 18-HEPE–derived lipid mediator RvE1, i.e., ERV1/ChemR23, as a key player in atherosclerosis.